logo
Plus   Neg
Share
Email

Court Rules In Favor Of Monsanto In Organic Seed Growers Litigation

Monsanto Co. (MON) announced that the U.S. District Court for the Southern District of New York has dismissed a lawsuit brought by The Organic Seed Growers and Trade Association or OSGATA and dozens of other plaintiff growers and organizations against the Company.

OSGATA and plaintiffs in the case alleged that they did not want to grow crops containing Monsanto's biotechnology traits but feared a patent-infringement lawsuit in the event the company's traits happened to enter their fields inadvertently through, for example, cross-pollination.

The company said the court rejected the lawsuit finding that OSGATA and plaintiffs had engaged in a "transparent effort to create a controversy where none exists."

The court also held that there was no "case or controversy" on the matter as Monsanto had not taken any action or even suggested to take any action against any of the plaintiffs, Monsanto said.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT